Increased iron deposition in nucleus accumbens associated with disease progression and chronicity in migraine.
Chronicity
Disease burden
Iron deposition
Migraine
Neuroimaging biomarkers
Nucleus accumbens
Journal
BMC medicine
ISSN: 1741-7015
Titre abrégé: BMC Med
Pays: England
ID NLM: 101190723
Informations de publication
Date de publication:
07 04 2023
07 04 2023
Historique:
received:
14
01
2023
accepted:
29
03
2023
medline:
10
4
2023
entrez:
6
4
2023
pubmed:
7
4
2023
Statut:
epublish
Résumé
Migraine is one of the world's most prevalent and disabling diseases. Despite huge advances in neuroimaging research, more valuable neuroimaging markers are still urgently needed to provide important insights into the brain mechanisms that underlie migraine symptoms. We therefore aim to investigate the regional iron deposition in subcortical nuclei of migraineurs as compared to controls and its association with migraine-related pathophysiological assessments. A total of 200 migraineurs (56 chronic migraine [CM], 144 episodic migraine [EM]) and 41 matched controls were recruited. All subjects underwent MRI and clinical variables including frequency/duration of migraine, intensity of migraine, 6-item Headache Impact Test (HIT-6), Migraine Disability Assessment (MIDAS), and Pittsburgh Sleep Quality Index (PSQI) were recorded. Quantitative susceptibility mapping was employed to quantify the regional iron content in subcortical regions. Associations between clinical variables and regional iron deposition were studied as well. Increased iron deposition in the putamen, caudate, and nucleus accumbens (NAC) was observed in migraineurs more than controls. Meanwhile, patients with CM had a significantly higher volume of iron deposits compared to EM in multiple subcortical nuclei, especially in NAC. Volume of iron in NAC can be used to distinguish patients with CM from EM with a sensitivity of 85.45% and specificity of 71.53%. As the most valuable neuroimaging markers in all of the subcortical nuclei, higher iron deposition in NAC was significantly associated with disease progression, and higher HIT-6, MIDAS, and PSQI. These findings provide evidence that iron deposition in NAC may be a biomarker for migraine chronicity and migraine-related dysfunctions, thus may help to understand the underlying vascular and neural mechanisms of migraine. ClinicalTrials.gov, number NCT04939922.
Sections du résumé
BACKGROUND
Migraine is one of the world's most prevalent and disabling diseases. Despite huge advances in neuroimaging research, more valuable neuroimaging markers are still urgently needed to provide important insights into the brain mechanisms that underlie migraine symptoms. We therefore aim to investigate the regional iron deposition in subcortical nuclei of migraineurs as compared to controls and its association with migraine-related pathophysiological assessments.
METHODS
A total of 200 migraineurs (56 chronic migraine [CM], 144 episodic migraine [EM]) and 41 matched controls were recruited. All subjects underwent MRI and clinical variables including frequency/duration of migraine, intensity of migraine, 6-item Headache Impact Test (HIT-6), Migraine Disability Assessment (MIDAS), and Pittsburgh Sleep Quality Index (PSQI) were recorded. Quantitative susceptibility mapping was employed to quantify the regional iron content in subcortical regions. Associations between clinical variables and regional iron deposition were studied as well.
RESULTS
Increased iron deposition in the putamen, caudate, and nucleus accumbens (NAC) was observed in migraineurs more than controls. Meanwhile, patients with CM had a significantly higher volume of iron deposits compared to EM in multiple subcortical nuclei, especially in NAC. Volume of iron in NAC can be used to distinguish patients with CM from EM with a sensitivity of 85.45% and specificity of 71.53%. As the most valuable neuroimaging markers in all of the subcortical nuclei, higher iron deposition in NAC was significantly associated with disease progression, and higher HIT-6, MIDAS, and PSQI.
CONCLUSIONS
These findings provide evidence that iron deposition in NAC may be a biomarker for migraine chronicity and migraine-related dysfunctions, thus may help to understand the underlying vascular and neural mechanisms of migraine.
TRIAL REGISTRATION
ClinicalTrials.gov, number NCT04939922.
Identifiants
pubmed: 37024948
doi: 10.1186/s12916-023-02855-1
pii: 10.1186/s12916-023-02855-1
pmc: PMC10080952
doi:
Substances chimiques
Iron
E1UOL152H7
Banques de données
ClinicalTrials.gov
['NCT04939922']
Types de publication
Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
136Informations de copyright
© 2023. The Author(s).
Références
Neurology. 1998 Nov;51(5):1465-9
pubmed: 9818884
Int J Neurosci. 1988 Jul;41(1-2):29-34
pubmed: 3045040
Neuroimage. 2015 Nov 15;122:385-98
pubmed: 26216277
JAMA. 2006 Jul 19;296(3):283-91
pubmed: 16849661
Mol Psychiatry. 2021 Sep;26(9):4616-4632
pubmed: 32612250
J Magn Reson Imaging. 2015 Dec;42(6):1592-600
pubmed: 25960320
J Headache Pain. 2022 Jun 27;23(1):72
pubmed: 35761188
Clin Radiol. 2022 Nov;77(11):833-839
pubmed: 35786315
Pain. 1995 Jan;60(1):3-38
pubmed: 7715939
Free Radic Biol Med. 1991;10(2):161-9
pubmed: 2016074
Sci Data. 2018 Apr 17;5:180063
pubmed: 29664465
Neuroimage. 2012 Feb 1;59(3):2625-35
pubmed: 21925274
Biomed Pharmacother. 2001 Jul;55(6):333-9
pubmed: 11478586
Neurobiol Aging. 2009 Mar;30(3):337-52
pubmed: 17869382
Nat Neurosci. 2012 Jul 01;15(8):1117-9
pubmed: 22751038
Headache. 2001 Jul-Aug;41(7):629-37
pubmed: 11554950
Front Neurosci. 2021 Feb 18;15:618435
pubmed: 33679303
Brain. 2017 Aug 1;140(8):2112-2119
pubmed: 28899019
Front Neurol. 2020 Nov 27;11:563916
pubmed: 33329306
J Neurosci. 2013 May 15;33(20):8827-40
pubmed: 23678125
Hum Brain Mapp. 2014 Jun;35(6):2698-713
pubmed: 24038837
Neuroimage. 2021 May 1;231:117701
pubmed: 33484853
Nat Rev Neurosci. 2011 Sep 20;12(10):570-84
pubmed: 21931334
J Clin Invest. 2004 May;113(10):1447-55
pubmed: 15146242
IEEE Trans Med Imaging. 2019 Jun;38(6):1347-1357
pubmed: 30561341
Mol Pain. 2022 Jan-Dec;18:17448069221074987
pubmed: 35083927
J Clin Neurol. 2019 Oct;15(4):448-453
pubmed: 31591831
Headache. 2012 Feb;52(2):236-43
pubmed: 22188387
Magn Reson Med. 2018 May;79(5):2795-2803
pubmed: 29023982
J Neuropathol Exp Neurol. 2006 Mar;65(3):199-203
pubmed: 16651881
Cephalalgia. 2010 May;30(5):599-609
pubmed: 19614702
Science. 2014 Aug 1;345(6196):535-42
pubmed: 25082697
Cereb Cortex. 2011 Feb;21(2):435-48
pubmed: 20562317
Neuroimage. 2021 Feb 15;227:117611
pubmed: 33309901
Nature. 2014 Nov 13;515(7526):185-7
pubmed: 25391944
PLoS One. 2017 Apr 19;12(4):e0176130
pubmed: 28423027
J Cereb Blood Flow Metab. 1999 Feb;19(2):115-27
pubmed: 10027765
Neuroimage. 2021 Jan 1;224:117433
pubmed: 33035667
Neuron. 2018 Mar 7;97(5):1004-1021
pubmed: 29518355
Neuroimage. 2022 Dec 1;264:119683
pubmed: 36243270
Front Neurol. 2018 Feb 28;9:95
pubmed: 29541053
Neurology. 2015 Feb 17;84(7):688-95
pubmed: 25609757
Neurobiol Aging. 2007 Mar;28(3):414-23
pubmed: 16563566
Mol Pain. 2021 Jan-Dec;17:17448069211020894
pubmed: 34056969
Neurol Sci. 2010 Jun;31 Suppl 1:S155-8
pubmed: 20464610
Magn Reson Med. 2011 Sep;66(3):777-83
pubmed: 21465541
Pain. 2013 Dec;154 Suppl 1:
pubmed: 24347803
Headache. 2013 Sep;53(8):1262-77
pubmed: 23848170
J Headache Pain. 2017 Dec;18(1):77
pubmed: 28744704
Neurology. 2019 Mar 5;92(10):e1076-e1085
pubmed: 30709968
Brain Res Bull. 2001 May 15;55(2):155-64
pubmed: 11470311
Headache. 2005 Jul-Aug;45(7):904-10
pubmed: 15985108
Cell Mol Life Sci. 2016 Jan;73(1):57-77
pubmed: 26403789
Brain Behav. 2019 Jan;9(1):e01138
pubmed: 30548431
Science. 2013 Oct 18;342(6156):373-7
pubmed: 24136970
Exp Mol Med. 2011 Feb 28;43(2):121-8
pubmed: 21278483
IEEE Trans Med Imaging. 2010 Feb;29(2):273-81
pubmed: 19502123
Magn Reson Med. 2014 Mar;71(3):1151-7
pubmed: 23666788
BMJ. 2014 Mar 24;348:g1416
pubmed: 24662044
Am J Clin Nutr. 1989 Sep;50(3 Suppl):618-25; discussion 625-9
pubmed: 2570524
Brain Sci. 2021 Feb 13;11(2):
pubmed: 33668449
Mol Pain. 2011 Sep 21;7:71
pubmed: 21936901
J Neurosci. 2016 Jan 13;36(2):364-74
pubmed: 26758829
Neurotherapeutics. 2007 Jul;4(3):371-86
pubmed: 17599703
Nat Commun. 2017 Sep 29;8(1):734
pubmed: 28963505
Proc Natl Acad Sci U S A. 2020 May 5;117(18):10015-10023
pubmed: 32312809
Cephalalgia. 2009 Mar;29(3):351-9
pubmed: 19025553
Ann Indian Acad Neurol. 2015 Jul-Sep;18(3):298-302
pubmed: 26425007
Neuron. 2010 Apr 15;66(1):149-60
pubmed: 20399736
Front Neurol. 2022 Aug 26;13:955298
pubmed: 36090858
Lancet. 1977 May 14;1(8020):1034-6
pubmed: 67489